Somapacitan
Somapacitan is a long-acting recombinant human growth hormone analog with a fatty acid conjugate that facilitates reversible albumin binding, extending its half-life to allow once-weekly subcutaneous administration for the treatment of growth hormone deficiency in adults. By mimicking endogenous GH signaling through the GH receptor, it stimulates IGF-1 production, promotes protein anabolism, and improves body composition in GH-deficient patients. Once-weekly dosing offers a significant convenience advantage over daily GH formulations.
分子量
1310.5000 g/mol
LogP
-2.10
TPSA
544.00 Ų
リピンスキーの五則
不適合
作用機序
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
2D構造
Cite this structure
Embed this structure
SMILES
C=C(CCCCCCCCCCCCCCCc1nnn[nH]1)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)N[C@@H](CCCCNC(=O)CSC[C@H](N)C(=O)O)C(N)=O)C(=O)O)C(=O)O
InChI
InChI=1S/C55H97N13O19S2/c1-40(18-13-11-9-7-5-3-2-4-6-8-10-12-14-20-45-64-67-68-65-45)66-89(82,83)35-17-21-46(69)59-27-29-84-32-34-87-37-50(73)63-44(55(80)81)23-25-48(71)62-43(54(78)79)22-24-47(70)60-28-30-85-31-33-86-36-49(72)61-42(52(57)75)19-15-16-26-58-51(74)39-88-38-41(56)53(76)77/h41-44,66H,1-39,56H2,(H2,57,75)(H,58,74)(H,59,69)(H,60,70)(H,61,72)(H,62,71)(H,63,73)(H,76,77)(H,78,79)(H,80,81)(H,64,65,67,68)/t41-,42-,43-,44-/m0/s1
Molecular Formula
C54H95N13O20S2
HBD / HBA
13 / 25
回転可能結合数
59
重原子数
89
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Somapacitan is a long-acting recombinant human growth hormone analog with a fatty acid conjugate that facilitates reversible albumin binding, extending its half-life to allow once-weekly subcutaneous administration for the treatment of growth hormone deficiency in adults. By mimicking endogenous GH signaling through the GH receptor, it stimulates IGF-1 production, promotes protein anabolism, and improves body composition in GH-deficient patients. Once-weekly dosing offers a significant convenience advantage over daily GH formulations.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Somapacitan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707290. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 129894493. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="somapacitan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/somapacitan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/somapacitan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/somapacitan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="somapacitan"></drugfyi-drug>